Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 févr. 2023 07h00 HE | Source: EuMentis Therapeutics, Inc.

EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury

EuMentis is developing novel therapeutics with clinically validated mechanisms for the treatment of neurodevelopmental and neuropsychiatric conditionsEuMentis plans to initiate Phase 2 clinical trials...
08 févr. 2023 07h00 HE | Source: EuMentis Therapeutics, Inc.

EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury

Under the DoD award, EuMentis will conduct preclinical TBI studies in validated large animal model in collaboration with Dr. Todd Killbaugh at the Children’s Hospital of Philadelphia (CHOP) and plans...